Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HX575 epoetin alfa safety in CKD
NCT00632125Phase 4Completed
- Sponsor
- Sandoz
- Start
- Jul 2008
- Primary completion
- Mar 2010
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 10
01
Overview
A Phase 4 trial of epoetin alfa HX575 in anemia of chronic kidney disease (CKD-A), sponsored by Sandoz. Started Jul 2008; status: completed.
02
Drugs
epoetin alfa HX575
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT00632125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00632125.